Serum Chemokine Ligand 5 (CCL5/RANTES) Level Might be Utilized as a Predictive Marker of Tumor Behavior and Disease Prognosis in Patients with Gastric Adenocarcinoma
详细信息 查看全文
- 作者：Ali Reza Sima (1)
Hamid Reza Sima (2)
Houshang Rafatpanah (3)
Hanieh Hosseinnezhad (4)
Kamran Ghaffarzadehgan (5)
Narges Valizadeh (3)
Mostafa Mehrabi Bahar (6)
Hamid Reza Hakimi (7)
Anahita Masoom (8)
Amin Noorbakhsh (9)
Nahid Razavi Satvati (9)
Hamid Reza Raziee (10) - 关键词：CCL5 chemokine ; Stomach neoplasms ; Disease progression ; Prognosis
- 刊名：Journal of Gastrointestinal Cancer
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：45
- 期：4
- 页码：476-480
- 全文大小：220 KB
- 参考文献：1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467-7. CrossRef
2. Malekzadeh R, Derakhshan M, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med. 2009;12(6):576-3.
3. Schall TJ, Bacon KB. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol. 1994;6(6):865-3. CrossRef
4. Balkwill F. Chemokine biology in cancer. Semin Immunol. 2007;15(1):49-5. CrossRef
5. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nat. 2001;410(6824):50-. CrossRef
6. Murphy P. Chemokines and the molecular basis of cancer metastasis. N Engl J Med. 2001;345(11):833-. CrossRef
7. Singh S, Sadanandam A, Singh R. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev. 2007;26(3-):453-7. CrossRef
8. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 1999;59(18):4681-.
9. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002;62(4):1093-02.
10. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 2003;63(23):8360-.
11. Eissa SA, Zaki SA, El-Maghraby SM, Kadry DY. Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Nat Cancer Inst. 2005;17(1):51-.
12. Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E, et al. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res. 2006;12(15):4474-. CrossRef
13. Niwa Y, Akamatsu H, Niwa H. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res. 2001;7(2):285-.
14. Tsukishiro S, Suzumori N, Nishikawa H. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Gynecol Oncol. 2006;102(3):542-. CrossRef
15. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate. 2006;66(2):124-4. CrossRef
16. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, et al. Elevated levels of circulating platelet micro particles. VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003;39(2):184-1. CrossRef
17. Okita K, Furuhata T, Kimura Y, Kawakami M, Yamaguchi K, Tsuruma T, et al. The interplay between gastric cancer cell lines and PBMCs mediated by the CC chemokine RANTES plays an important role in tumor progression. J Exp Clin Cancer Res. 2005;24(3):439-6.
18. Sugasawa H, Ichikura T, Tsujimoto H, Kinoshita M, Morita D, Ono S, et al. Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. J Surg Oncol. 2008;97(5):445-. CrossRef
19. Sugasawa H, Ichikura T, Kinoshita M, Ono S, Majima T, Tsujimoto H, et al. Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination. Int J Cancer. 2008;122(11):2535-1. Anahita Masoom (8)
Amin Noorbakhsh (9)
Nahid Razavi Satvati (9)
Hamid Reza Raziee (10)
1. Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Science, Tehran, 14117, Iran
2. Department of Medicine, James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10468, USA
3. Inflammation and Inflammatory Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4. Vice Chancellery for Health, Mashhad University of Medical Sciences, Mashhad, Iran
5. Department of Pathology, Razavi Hospital, Mashhad, Iran
6. Surgical Oncology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
7. Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
8. School of Medicine, Islamic Azad University, Mashhad Branch, Mashhad, Iran
9. School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
10. Department of Radiation Oncology, University of Toronto, Toronto, Canada - ISSN：1941-6636
文摘
Purpose Gastric cancer is the second leading cause of cancer-related deaths worldwide and the most common gastrointestinal cancer in Iran. Chemokine ligand 5 (CCL5/RANTES) is one of the most potent angiogenic factors that plays an important role in tumor growth, invasion, and metastasis. We aimed to assess the serum level of CCL5 in patients with gastric adenocarcinoma and its relation with histological grade and tumor stage, as well as the disease prognosis. Methods Seventy-four patients with gastric adenocarcinoma that had undergone gastrectomy and 96 non-tumoral cases in which gastric cancer was ruled out by gastroscopy and biopsy were enrolled. Demographic and epidemiological characteristics and patient survival data were reviewed. Histological type, grade, and tumor stage (TNM) were determined by a single expert pathologist. Helicobacter pylori infection status and CCL5 serum level were measured by ELISA. Data were analyzed using SPSS software version 16. Results Patients with gastric adenocarcinoma had significantly higher serum CCL5 level compared with control group (P--001). Higher serum CCL5 levels were associated with lower histological differentiation (P--001), higher depth of tumor invasion (P--022), more frequent lymph nodes involvement (P--028), and advanced tumor stage (P--002). The overall survival of patients with CCL5 levels higher than 70,671?pg/ml was significantly lower than those with lower than this cutoff (P--043). Conclusions Serum CCL5 levels might be utilized as a predictive marker of tumor behavior and disease prognosis in patients with gastric adenocarcinoma. Further studies to assess tissue expression of CCL5 and its gene polymorphisms are suggested.